Obecabtagene autoleucel for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukaemia

13 June 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

PHARMAC declines inactive medicine applications

18 June 2025 - PHARMAC has declined 48 inactive funding applications so that it is clearer what medicines are currently ...

Read more →

New Chief Executive for PHARMAC

17 June 2025 - PHARMAC’s Board has appointed a new Chief Executive to lead the organisation. ...

Read more →

EMA publishes agenda for 16-19 June 2025 CHMP meeting

16 June 2025 - The EMA has published a draft agenda for this week's CHMP meeting. ...

Read more →

NICE leads the way in approving breakthrough treatment for multiple myeloma

13 June 2025 - People in England will become the first in the world to receive belantamab mafodotin for this indication ...

Read more →

AbbVie’s Epkinly, Eisai’s Lenvima pass reimbursement review; Janssen’s Tecvayli fails

11 June 2025 - AbbVie Korea's Epkinly (epcoritamab), a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma ...

Read more →

DoH publishes revised agenda for July 2025 PBAC meeting (version 4)

10 June 2025 - The DoH has published a revised agenda for next month's PBAC meeting. ...

Read more →

SMC - June 2025 decisions

9 June 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...

Read more →

Biogen disappointed by INESSS recommendation on Skyclarys and its impact on Quebec patients with Friedreich ataxia

5 June 2025 - Biogen Canada is disappointed by INESSS's recommendation against listing Skyclarys (omaveloxolone), despite its therapeutic potential for ...

Read more →

DoH publishes revised agenda for May 2025 PBAC meeting in June!

4 June 2025 - The DoH has published a revised agenda for last month's PBAC meeting. ...

Read more →

RSV prophylaxis with nirsevimab: benefits for healthy children in the first RSV season

2 June 2025 - Children immunised with the antibody nirsevimab are significantly less likely to develop RSV-related lower respiratory tract infections. ...

Read more →

Garadacimab in hereditary angioedema: evidence of considerable additional benefit

2 June 2025 - An indirect comparison shows a significant reduction in the monthly rate of attacks and other benefits.  ...

Read more →

ICER publishes evidence report on treatment for secondary progressive multiple sclerosis

29 May 2025 - There are significant uncertainties regarding long term efficacy of tolebrutinib; ICER estimates that treatment would achieve ...

Read more →

ICER releases draft evidence report on treatments for spinal muscular atrophy

27 May 2025 - Public comment period now open until 24 June 2025; requests to make oral comment during public ...

Read more →

CHMP recommends EU approval of Roche’s Itovebi for PIK3CA mutated, ER positive, HER2 negative, advanced breast cancer

23 May 2025 - Positive recommendation based on Phase 3 INAVO120 data showing Itovebi (inavolisib) in combination with palbociclib and fulvestrant ...

Read more →